TP53 and colorectal cancer: These data suggest that activating p53 through the nanobody-kinase system (p53Nb-KA) enhances the effectiveness of both 5-FU and Oxaliplatin in HCT116 colorectal cancer cells, highlighting the potential of combining targeted p53 activation with traditional chemotherapeutic drugs to improve treatment outcomes.